Using chitosan-stabilized, hyaluronic acid-modified selenium nanoparticles to deliver CD44-targeted <i>PLK1</i> siRNAs for treating bladder cancer-Reference-Cited by-同舟云学术

Using chitosan-stabilized, hyaluronic acid-modified selenium nanoparticles to deliver CD44-targeted PLK1 siRNAs for treating bladder cancer

Published:2023-02 Issue:3 Volume:18 Page:259-277
ISSN:1743-5889
Container-title:Nanomedicine
language:en
Short-container-title:Nanomedicine

Author:

Shahidi Maryamsadat¹^ORCID,Abazari Omid¹^ORCID,Dayati Parisa²^ORCID,Reza Javad Zavar¹^ORCID,Modarressi Mohammad Hossein³^ORCID,Tofighi Davood⁴^ORCID,Haghiralsadat Bibi Fatemeh⁵^ORCID,Oroojalian Fatemeh⁶⁷^ORCID

Affiliation:

1. Department of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences & Health Services, Yazd, 89151, Iran

2. Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, 14115, Iran

3. Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, 14176, Iran

4. Department of Psychology, University of New Mexico, Albuquerque, NM 87131, USA

5. Medical Nanotechnology & Tissue Engineering Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, 89151, Iran

6. Department of Advanced Technologies, School of Medicine, North Khorasan University of Medical Sciences, Bojnūrd, 94149, Iran

7. Natural Products & Medicinal Plants Research Center, North Khorasan University of Medical Sciences Bojnūrd, 94149, Iran

Abstract

Aims: Achieving an effective biocompatible system for siRNAs delivery to the tumor site remains a significant challenge. Materials & methods: Selenium nanoparticles (SeNPs) modified by chitosan (CS) and hyaluronic acid (HA) were fabricated for PLK1 siRNAs ( siPLK1) delivery to the bladder cancer cells. The HA-CS-SeNP@siPLK1 efficacy was evaluated using in vitro and in vivo models. Results: HA-CS-SeNP@siPLK1 was selectively internalized into T24 cells through clathrin-mediated endocytosis. Treatment with HA-CS-SeNP@siPLK1 successfully silenced the PLK1 gene, inhibited cell proliferation and induced cell cycle arrest in vitro. HA-CS-SeNP@siPLK1 could also inhibit tumor growth in vivo without causing systemic toxicity. Conclusion: Our results suggest that HA-CS-SeNPs may provide a good vehicle for delivering siPLK1 to the bladder tumor site.

Funder

Shahid Sadoughi University of Medical Sciences

Publisher

Future Medicine Ltd

Subject

Development,General Materials Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/nnm-2022-0198

Reference73 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Tumor budding correlates with tumor invasiveness and predicts worse survival in pT1 non-muscle-invasive bladder cancer

3. Novel and emerging approaches in the management of non-muscle invasive urothelial carcinoma

4. Bladder-sparing treatment options in localized muscle-invasive bladder cancer

5. Oncological outcomes, quality of life outcomes and complications of partial cystectomy for selected cases of muscle-invasive bladder cancer

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A quaternary ammonium-based nanosystem enables delivery of CRISPR/Cas9 for cancer therapy;Biomaterials Science;2024

2. Nanomedicine innovations in spinal cord injury management: Bridging the gap;Environmental Research;2023-10

3. Ginger’s Antiapoptotic and Antioxidant Effects on Ovaries of Cyclophosphamide-therapied Rats;Current Pharmaceutical Design;2023-08